JP2005516004A - 新形成の治療 - Google Patents

新形成の治療 Download PDF

Info

Publication number
JP2005516004A
JP2005516004A JP2003550776A JP2003550776A JP2005516004A JP 2005516004 A JP2005516004 A JP 2005516004A JP 2003550776 A JP2003550776 A JP 2003550776A JP 2003550776 A JP2003550776 A JP 2003550776A JP 2005516004 A JP2005516004 A JP 2005516004A
Authority
JP
Japan
Prior art keywords
thc
apoptosis
cells
receptor
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003550776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516004A5 (enExample
Inventor
ナガーカッティ，ミッツィ
ナガーカッティ，プラカシュ
マクカリップ，ロバート
ロムバード，キャセリン
リュー，ションギョ
Original Assignee
ヴァージニア コモンウェルス ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァージニア コモンウェルス ユニバーシティ filed Critical ヴァージニア コモンウェルス ユニバーシティ
Publication of JP2005516004A publication Critical patent/JP2005516004A/ja
Publication of JP2005516004A5 publication Critical patent/JP2005516004A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003550776A 2001-12-07 2002-12-09 新形成の治療 Pending JP2005516004A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33673201P 2001-12-07 2001-12-07
PCT/US2002/039310 WO2003049727A1 (en) 2001-12-07 2002-12-09 Treatment of neoplasia

Publications (2)

Publication Number Publication Date
JP2005516004A true JP2005516004A (ja) 2005-06-02
JP2005516004A5 JP2005516004A5 (enExample) 2006-02-02

Family

ID=23317407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003550776A Pending JP2005516004A (ja) 2001-12-07 2002-12-09 新形成の治療

Country Status (6)

Country Link
US (1) US20040259936A1 (enExample)
EP (1) EP1461027A4 (enExample)
JP (1) JP2005516004A (enExample)
AU (1) AU2002357114B2 (enExample)
CA (1) CA2468794A1 (enExample)
WO (1) WO2003049727A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509365A (ja) * 2006-11-13 2010-03-25 ノバルティス アーゲー Ｋｓｐ阻害剤としての置換ピラゾールおよびトリアゾール化合物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632955B2 (en) * 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
US7528165B2 (en) * 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
WO2005023232A2 (en) * 2003-09-04 2005-03-17 Affibody Ab Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
EP1736775A4 (en) * 2004-04-12 2008-03-12 Takeda Pharmaceutical NEW LIGAND OF A G-PROTEIN-COUPLED RECEPTOR PROTEIN AND USE THEREOF
TWI360539B (en) 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
EP2470508A1 (en) 2009-08-28 2012-07-04 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CA2789151A1 (en) 2010-02-08 2011-08-11 Allergan, Inc. Pyridazine derivatives useful as cannabinoid-2 agonists
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
MX392150B (es) 2011-02-25 2025-03-21 Arena Pharm Inc Moduladores de receptores canabinoides.
JP5945554B2 (ja) 2011-02-25 2016-07-05 アリーナ ファーマシューティカルズ， インコーポレイテッド 縮合型アザ環の結晶形およびその調製プロセス（カンナビノイド受容体モジュレーター）
WO2016085941A1 (en) 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
CN114096241A (zh) * 2019-05-16 2022-02-25 技术研究及发展基金有限公司 大麻素及其用途
CN115282279B (zh) * 2022-08-08 2024-03-12 暨南大学附属第一医院（广州华侨医院） CNR2通过介导DCs成熟及功能作为脓毒症急性肺损伤治疗靶点的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1271266B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
CA2340444A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Cannabinoids selective for the cb2 receptor
CA2387892A1 (en) * 1999-10-18 2001-04-26 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
FR2800372B1 (fr) * 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
JP2004502642A (ja) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509365A (ja) * 2006-11-13 2010-03-25 ノバルティス アーゲー Ｋｓｐ阻害剤としての置換ピラゾールおよびトリアゾール化合物

Also Published As

Publication number Publication date
EP1461027A1 (en) 2004-09-29
WO2003049727A1 (en) 2003-06-19
AU2002357114B2 (en) 2008-07-24
US20040259936A1 (en) 2004-12-23
AU2002357114A1 (en) 2003-06-23
CA2468794A1 (en) 2003-06-19
EP1461027A4 (en) 2005-09-07

Similar Documents

Publication Publication Date Title
Ke et al. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses
Maestroni et al. Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice
AU2002357114B2 (en) Treatment of neoplasia
RU2303452C2 (ru) Применение ингибиторов сох-2 для предупреждения иммунодефицита
EP2217231B1 (en) Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management
JP6000313B2 (ja) ３，３’−ジインドリルメタン免疫活性化組成物
Inoue et al. Resveratrol improves salivary dysfunction in a non-obese diabetic (NOD) mouse model of Sjögren’s syndrome
US11541030B2 (en) Methods for the treatment of inflammation associated with infection
ITMI971789A1 (it) Farmaco attivo nel ridurre la produzione di proteina mcp-1
Ben-Eliyahu et al. Timing within the oestrous cycle modulates adrenergic suppression of NK activity and resistance to metastasis: possible clinical implications
Liu et al. Effect of auranofin, an antirheumatic drug, on neutrophil apoptosis
CA2583464A1 (en) Ecteinascidin compounds as anti -inflammatory agents
Saito et al. Troglitazone, a selective ligand for PPARγ, induces cell-cycle arrest in human oral scc cells
AU2002252338B2 (en) Taurine compounds
AU2002252338A1 (en) Taurine compounds
CN105232568B (zh) 木蝴蝶苷b的应用及含木蝴蝶苷b的药物
CN116173004A (zh) 硝呋齐特在制备用于预防或治疗肾上腺皮质癌的药物中的用途
Helvaci et al. Smoking and sickle cell diseases
Ogino et al. Indomethacin acts as an antitumor and anticachexic agent in colon 26-bearing CDF1 mice
EP1656147B1 (en) Diflunisal for the treatment of cancer
CN110063957A (zh) 厄洛替尼在制备flt3抑制剂类药物中的用途
Desai et al. Effects of Anesthesia on Cancer
Wang et al. Selective Inhibition of Natural Killer but not Natural Cytotoxic Activity in a Cloned Cell Line by Delta‐9‐Tetrahydrocannabinol
WO2024240025A1 (zh) 一种联合用药物组合物及其应用
AU2001270902B2 (en) Use of COX-2 inhibitors for preventing immunodeficiency

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090501

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090805

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091009